Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer

BACKGROUND: Hu-rhEGF-rP64k/Mont is a biotechnology product for the treatment of advanced non-small cell lung cancer (NSCLC). The vaccine induces a neutralizing antibody-mediated immune response, against the normal circulating self-protein antigen epidermal growth factor (EGF), which prevents its bin...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Puyuan, Wang, Hongyu, Yang, Sheng, Han, Xiaohong, Sun, Yan, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902871/
https://www.ncbi.nlm.nih.gov/pubmed/29661145
http://dx.doi.org/10.1186/s12865-018-0249-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902871/
https://www.ncbi.nlm.nih.gov/pubmed/29661145
http://dx.doi.org/10.1186/s12865-018-0249-9

Ejemplares similares